Currently, The Mesothelioma Treatment Center has several clinical trials for which we are actively recruiting patients. Clinical trials are studies in which new cutting-edge methods for the treatment of mesothelioma are being tested and although they cannot guarantee a cure, they sometimes offer the best chance.
If you are considered eligible for any clinical trials that we are conducting, we will discuss that possibility with you. You will learn what your participation means for your health, for research, and for future patients, and you will learn what you will need to do to participate. Often, participation requires little more than for you to allow your biopsies to be included in the study, and perhaps a sample of your blood. If the trial is more extensive (i.e. a new chemotherapy or drug regimen), the possible benefits and risks will be explained to you completely before you agree to participate.
Open Clinical Trials
H-38140 A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, PHASE II STUDY OF INTRAVENOUS ANETUMAB RAVTANSINE (BAY 94-9343) OR VINORELBINE IN PATIENTS WITH ADVANCED OR METASTATIC MALIGNANT PLEURAL MESOTHELIOMA OVEREXPRESSING MESOTHELIN AND PROGRESSED ON FIRST LINE PLATINUM/PEMETREXED-BASED CHEMOTHERAPY
This clinical trial is designed to compare the success of two different therapies — anetumab ravtansine and vinorelbine — as treatments for malignant pleural mesothelioma. Patients who participate in this study will receive one of the two drugs, and researchers will monitor several outcomes, including pulmonary function, drug safety, and quality of life. Researchers will also look at how the drug moves through the body and how the patient’s immune system responds to the drug.
H-36952 WINDOW OF OPPORTUNITY PHASE II STUDY OF MEDI4736 OR TREMELIMUMAB IN SURGICALLY RESECTABLE MALIGNANT MESOTHELIOMA
The area of the body that includes the tumor and the immediately surrounding tissues is called the “tumor microenvironment.” The microenvironment comprises several types of immune cells, including T-cells. For this study, two therapies will be compared: MEDI4736 alone (monotherapy) and MEDI4736 + tremelimumab (combination therapy). Tumors from patients with mesothelioma will first be biopsied, then the patients will receive one of the two types of therapy. Finally, these patients will undergo surgical resection to remove the tumor. Researchers will examine the T-cells in the microenviroment of the tumors, comparing the samples collected “before” and “after” therapy for each patient. The researchers plan to characterize and understand how the two therapies change the properties of the T-cells in the microrenviroment of the tumor.
First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies.
This is a phase 1, open-label, multicenter, ascending-dose escalation study of REGN2810, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
This study has been designed to collect long-term follow-up information for patients who received REGN2810 in other clinical studies and to allow re-treatment for eligible patient.
Pending Clinical Trials
H-36460 PHASE I STUDY OF CYTOREDUCTIVE SURGERY AND HYPERTHERMIC INTRAOPERATIVE CHEMOTHERAPY WITH PEMETREXED AND CISPLATIN FOR MALIGNANT PLEURAL MESOTHELIOMAS
This study will examine several pharmacological properties of a new drug, pemetrexed, when it is given with a well-known chemotherapy, cisplatin. These drugs will be given to the participating patients using a technique called hyperthermic intraoperative chemotherapy, which means the drug is warmed and delivered locally to the tumor site during in-patient surgery. Patients that receive this treatment will be observed to see how they tolerate the drug, and side effects will be monitored closely.
H-36302 RETROSPECTIVE COLLECTION OF CLINICAL DATA ON PATIENTS UNDERGOING THORACIC SURGERY
The purpose of this clinical trial is to generate and maintain a large, secure database of information on patients and their overall medical experience involving thoracic surgeries, including those for mesothelioma treatment. As more patients are added and the database grows, we will be able to study these data in subsets based on certain commonalities between patients (i.e. all female patients, or all patients with a stage II tu or), looking for trends in prognosis, success, and failure. From these data, we will be able to learn what combinations of disease staging, treatment, and other patient factors lead to the best results. With these data, we will be able to make informed choices on how to modify our future standards of care to maximize patient success.
H-35782 THE IMMUNE LANDSCAPE OF THORACIC MALIGNANCIES
The purpose of this clinical trial is to collect information on the types of immune cells found in and around the tumor site(s). This information will tell us how a patient’s immune system is reacting to the presence of the tumor. When we combine this information with other information on patients’ prognoses, we will be able to identify the types of immune responses seen in patients that recover well from mesothelioma. The goal of learning this information is to explore the possibility of manipulating the immune system to favor improved prognosis using additional drugs or other therapies.